24 May 2017 - Biogen’s Fampyra has been granted a standard approval by European regulators on the back of late-stage data supporting its use to improve walking in patients with multiple sclerosis.

The drug won conditional approval back in 2011 on the back of promising data on its benefit, which was subsequently confirmed in the Phase III ENHANCE trial.

According to the results, significantly more patients taking Fampyra (fampridine) achieved a clinically meaningful improvement in walking ability compared to patients taking placebo (43.2 percent versus 33.6 percent, respectively).

Read Pharma Times article